How to Write a Cancer Letters Cover Letter (With Template)

Cancer Letters covers basic and translational oncology: molecular genetics and cell biology of cancer, tumor microenvironment, metastasis, cancer immunology, radiation biology, viral oncology, drug resistance, biomarkers, and experimental therapeutics for personalized cancer medicine. The handling editor is reading to decide whether your manuscript advances a mechanism with translational reach, not whether it is competent.

The order matters. Cancer Letters editors scan for mechanism-and-translation signal density. A letter that names the mechanism, the evidence, the translational fit, and the declarations in that sequence is easier to route and harder to desk-reject.

The single most common weak opener at this journal is the descriptive one. Compare the two below; the difference is exactly what the editor is screening for.

Weak opener (avoid this):

We investigated the expression of gene X in tumor samples and found it correlated with poor prognosis using several experimental approaches.

Why it fails: there is no mechanism, no functional claim, no translational consequence, and nothing that tells the editor why a mechanism-focused oncology journal should review it.

Strong opener (do use this shape):

We show that gene X drives metastatic colonization in pancreatic cancer by activating the [pathway] axis, and that genetic and pharmacologic disruption of X suppresses metastasis in patient-derived xenografts, establishing X as a candidate therapeutic vulnerability.

Why it works: the mechanism is concrete, the functional and in-vivo evidence is named, and the translational hook (a candidate therapeutic vulnerability) is exactly the kind of claim Cancer Letters exists to publish.

Editorial Manager and Elsevier policy both expect an explicit author agreement. The cleanest version states originality, non-duplication, and unanimous author approval in two sentences:

We confirm that this manuscript is the authors' original work, has not been published previously, and is not under consideration for publication elsewhere. All authors have seen and approved the final version of the manuscript and agree to its submission to Cancer Letters.

Drop this into the declaration paragraph of the template above. It satisfies the non-duplication declaration and the all-authors-approved line in one place, and it matches the language Elsevier asks authors to confirm at submission.

Cancer Letters publishes more than one format, and the cover letter argument changes with the article type you name in the first line.

Source: Cancer Letters guide for authors and Elsevier editorial policy (accessed June 2026).

Name the article type explicitly. A handling editor who has to infer whether you meant an Original Article or a Letter is already routing your manuscript more slowly than the next one in the queue.

Cancer Letters and Elsevier handle most declarations through Editorial Manager fields and the manuscript itself, but the cover letter should still confirm the package is complete. Two things authors get wrong here, repeatedly.

First, suggested and opposed reviewers go in the Editorial Manager Review Preferences step, not the cover letter body. Supply at least 3 to 4 reviewers who are qualified on the mechanism, with no recent co-authorship and no shared-institution ties. If you want to exclude reviewers, name them in the opposed-reviewer field with a one-line, non-defamatory reason. You can reference your suggestions briefly in the letter, but the structured fields are where the editor actually reads them.

Second, the competing-interest, funding, and data-availability declarations are not optional. State competing interests (or their absence) for all authors, declare the funding source and grant numbers, and confirm a data availability statement with repository links for sequencing, transcriptomic, or proteomic data. For human-subject or animal work, the manuscript must carry ethics approval with specific IRB and IACUC numbers; vague "approval was obtained" language gets flagged at intake before the scope screen even begins.

Address the editor by name only if you can verify the current Editor-in-Chief or handling editor on the Cancer Letters editorial board page. Verify the current incumbent before quoting any name, because rosters change and a wrong name reads as carelessness at the exact moment the editor is deciding whether to keep reading.

Picture the handling editor on a Cancer Letters triage morning. They are reading dozens of cover letters and deciding within a minute or two whether each manuscript merits a closer look. They are not asking "is this competent work?" They are asking "does this establish a cancer-biology mechanism with translational reach, and can I find a reviewer for it?"

When we read letters from the editor's side of the desk, the ones that survive answer both questions in the first paragraph: a concrete mechanism claim, the functional evidence that backs it, and a translational hook the editor can use when discussing the paper internally. The letters that get desk-rejected make the editor go hunting in the manuscript for the contribution.

At a journal that desk-rejects 40 to 50 percent of submissions, making the editor hunt is the same as losing.

In our pre-submission review work with Cancer Letters submissions, the cover letter fails in three patterns far more often than the manuscript does, and each one predicts a desk rejection before a reviewer is ever invited. The Manusights pre-submission moat here is the editorial residue from screening cancer-biology manuscripts against this journal's mechanism-and-translation bar; the patterns below are testable against your own draft.

The abstract-in-disguise letter. Across our Cancer Letters pre-submission reviews, the most common failure is a cover letter that is a reformatted abstract. It describes the methods, lists the transcriptomic or proteomic datasets, and summarizes results, but never states the cancer-biology mechanism claim or the translational implication. The editor's question is not "what did you do?" but "why should I send this out?"

When the letter reads as a methods summary, it answers the wrong question and the manuscript enters the queue weaker than it needs to be. The fix is one sentence: state the mechanism in active voice, then point to the functional perturbation evidence that supports it.

The descriptive-without-mechanism pitch. Cancer Letters is built around mechanism, and the cover letter is where descriptive framing gets caught first. In manuscripts we review for Cancer Letters, letters that lead with "we observed expression of X" or "X correlated with prognosis" routinely draw the "where is the mechanism?" response at the desk. Editors expect functional evidence, such as knockouts, knockdowns, or mutants, named in the letter, not buried in the supplementary figures.

We coach authors to frame the observation in service of a mechanism question and to integrate in-vivo or patient-sample validation into the main argument, because a cover letter that names functional and in-vivo data signals a complete package before the editor opens a single figure.

The translational-fit gap. The third recurring pattern is a letter that argues subfield novelty without connecting the mechanism to a therapeutic, biomarker, or drug-resistance question. Cancer Letters places explicit emphasis on experimental therapeutics and targeted therapies for personalized cancer medicine; a cover letter that stops at "this advances our understanding of pathway Y" gives the editor no translational hook to justify the slot.

We see the strongest Cancer Letters letters close the loop in one sentence: this mechanism implies this intervention, this biomarker, or this resistance vulnerability. That single translational sentence is frequently the difference between a desk reject and an invitation to review.

A Cancer Letters cover letter and scope-fit check evaluates the manuscript and its framing against these three patterns before you submit.

• For portal mechanics, routing, and policy details, use the Cancer Letters submission guide.
• For target-fit context, see the Cancer Letters journal profile.
• For the general structure that applies across venues, see the cover letter for journal submission templates.

Use this page when the question is the cover letter itself; use the submission guide for upload logistics and the manuscript check for the editor-facing fit call.